Sir,
Somnambulism is a relatively common childhood parasomnia, affecting ~25% of children with sleep-related problem. [1] Attention deficit hyperactivity disorder (ADHD) is associated with various forms of sleep disorders. [2] Clonidine, an α-2 agonist, is used for psychiatric disorders such as ADHD, substance abuse, insomnias, and parasomnias. [3] Few studies have indicated a possible association of clonidine with somnambulism. Somnambulism was reported in a child who received 0.2 mg of clonidine. [4] Long-term use of intrathecal clonidine in a patient suffering from postoperative pain also complained of vivid dreams and night terror, which subsided with clonidine withdrawal. [5] We present a case of somnambulism associated with the use of clonidine in a patient of ADHD.
A 7-year-old male patient with a history of ADHD, oppositional defiant disorder and insomnia, presented with hyperactivity, restlessness, distractibility, and inattention causing poor academic performance. Initially, the patient was on 15 mg dexamphetamine-amphetamine extended release preparation with significant improvement in symptoms and school grades, but hyperactivity persisted during the evening along with insomnia which was likely related to the prescribed stimulant. The dose of stimulant was reduced to address drug-induced insomnia, and Vanderbilt teacher checklist was utilized to monitor for symptoms of ADHD. Insomnia persisted even with a reduced dose of stimulant. Subsequently, clonidine (0.1 mg) was added at bedtime to address insomnia. Clonidine was extremely helpful in inducing sleep. However, within 2 weeks of initiation of clonidine mother reported two episodes of sleepwalking. During these episodes, within 2 h of sleep onset, the patient would walk around the house, appeared confused, and had no recollection of the event once awake. Clonidine was discontinued with immediate resolution of symptoms. However, after 2 months of discontinuation of clonidine, insomnia re-emerged, and the patient had a retrial of clonidine. Again, there was a robust response to insomnia, but the patient experienced another episode of sleepwalking within 7 days of restarting clonidine. Somnambulism resolved again with discontinuation of medication and insomnia is currently managed with melatonin and sleep hygiene.
With this case, discontinuation of medication led to resolution of somnambulism, but re-emergence of insomnia, Somnambulism associated with the use of clonidine: A case report and review of the literature
"Precision psychiatry": A promising direction so far
Sir, After launching of "The Precision Medicine Initiative" in 2015, precision medicine has got new momentum, in recent years, at least in Western countries. [1] Precision medicine has been defined as "an emerging approach for treatment and prevention that takes each person's variability in genes, environment, and lifestyle" into account. [2] Interestingly, the foundation of precision medicine is not recent one; it dates back from Hippocrates in 400 BC to Claude Bernard, a physiologist in 19 th century. [3, 4] Archibald Gabbord, who talked about the importance of individual "chemical differences" in an article in 1902, is considered to be the father of precision medicine. [5, 6] What might have been the goal of precision medicine might have been borrowed from Gabbord as "The task of the practitioner is far more than to apply the knowledge supplied to him from the laboratories; he … calls upon his experience to guide him as to how he may best help the particular patient [manage his disease] with the least possible damage." [6] The dictionary definition of "precision is 'the quality, condition, or fact of being exact and accurate' and 'refinement in a measurement, calculation, or specification'." [7] Adoption of the term "precision psychiatry" may rightly be the first step toward that. [8, 9] The basic presumption of precision psychiatry remains in applying existing concepts and constructs of precision medicine along with developing newer ones in diagnosis and treatment in the field of clinical psychiatry. While, with the advent of newer technologies for assessment and management, precision medicine has potential to be more "quantitatively" precise, this is not the same in case of precision psychiatry. Research claims that precision psychiatry would not only be "quantitatively" different but would be different "qualitatively" also, thereby leading to a paradigm shift. Given the scenario where there is lack of clarity in pathophysiological mechanism of psychiatric disorders and symptoms, overlapping among them which is more complicated by symptom heterogeneity for a psychiatric diagnosis, it would not be far fletched to expect that "precision psychiatry", if it attains what it has envisioned to, shall bring a paradigm shift in clinical psychiatry. While a "causal" connection has been apparent for psychosocial factors, same for biological factors for psychiatric illness remained mostly inconclusive, thereby limiting the effectiveness of currently available management for psychiatric illnesses. One critical issue to understand regarding causation and course of mental illness is how multiples systems across mental apparatus overlap and failure of one element in the system does not lead to system-wide failure or how one or more elements are there for back up if other elements fail to function or intrinsic mechanisms exist for systemic stability. [9] Few other limiting factors in clinical psychiatry are in having symptom-based diagnosis instead of mechanism based, [10] in ascertaining prognosis, in predicting response to treatment and guiding treatment. To add to these challenges, there is epigenetics which disrupts the process of genetic maturation of an individual thereby altering disease process of a psychiatric disorder. Recently, Williams proposed a neural circuit-based taxonomy for anxiety and depression. [11] He elaborated about the putative types of dysfunction, which is not parallel to traditional diagnostic boundaries but covers the heterogeneity of depression and anxiety. For example, it has been a quite common experience to clinicians that two patients suffering from depression do not respond identically to an antidepressant despite identical sociodemographic and clinical profiles. With the help of "big data" (mentioned below), one would be able to predict and be precise to choose an antidepressants molecule individualized and précised for an index patient. Similarly, a patient
